Back

RNA interference therapy in transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials

31 August 2025 (11:25 - 11:35)
Organised by: Logo
Congress Presentation Part of: Therapeutic advances in amyloid cardiomyopathy Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Giang Son Arrighini

Bologna (Italy)

5 More presentations in this session

Presentation thumbnail
Tafamidis treatment significantly reduces the risk of recurrent cardiovascular-related hospitalisation in patients with early stage transthyretin amyloid cardiomyopathy
Doctor M. Grogan (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Echocardiographic assessments of ventricular function and cardiac structure with ALXN2220, an ATTR depleter: analysis from the open-label extension of study NI006-101
Doctor F. Aus Dem Siepen (Heidelberg, DE)
Abstract Slides Video
Presentation thumbnail
Combination therapy with sglt2-inhibitors and tafamidis in transthyretin cardiomyopathy
Doctor B. Forst (Phoenix, US)
Abstract Slides Video
Presentation thumbnail
HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
Doctor P. Garcia-Pavia (Majadahonda, ES)
Abstract Slides Video
Presentation thumbnail
The UNOS experience on heart transplantation for amyloid cardiomyopathy
Associate Professor A. Briasoulis (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Therapeutic advances in amyloid cardiomyopathy
Video

The Event

Event poster

ESC Congress 2025

31 August 2025 11:25 CET
You may be interested in
thumbnail
Congress Presentation
Long-term effects of patisiran on survival and cardiac parameters in patients with transthyretin-mediated cardiac amyloidosis: post hoc analysis of APOLLO-B and cardiac subpopulation of APOLLO OLE
thumbnail
Congress Session
Therapeutic advances in amyloid cardiomyopathy
thumbnail
Congress Session
Advances in amyloidosis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources